Literature DB >> 24690037

Family matters: sibling rivalry and bonding between p53 and p63 in cancer.

Rose-Anne Romano1, Satrajit Sinha.   

Abstract

The p53 family (p53, p63 and p73) is intimately linked with an overwhelming number of cellular processes during normal physiological as well as pathological conditions including cancer. The fact that these proteins are expressed in myriad isoforms, each with unique biochemical properties and distinct effects on tumorigenesis, complicates their study. A case in point is Squamous Cell Carcinoma (SCC) where p53 is often mutated and the ΔNp63 isoform is overexpressed. Given that p53 and p63 can hetero-dimerize, bind to quite similar DNA elements and share common co-factors, any alterations in their individual expression levels, activity and/or mutation can severely disrupt the family equilibrium. The burgeoning genomics data sets and new additions to the experimental toolbox are offering crucial insights into the complex role of the p53 family in SCC, but more mechanistic studies are needed.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  genomics; keratinocytes; p53 family; squamous cell carcinoma

Mesh:

Substances:

Year:  2014        PMID: 24690037     DOI: 10.1111/exd.12356

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  2 in total

1.  p63-dependent and independent mechanisms of nectin-1 and nectin-4 regulation in the epidermis.

Authors:  Maria Rosaria Mollo; Dario Antonini; Karen Mitchell; Paola Fortugno; Antonio Costanzo; Jill Dixon; Francesco Brancati; Caterina Missero
Journal:  Exp Dermatol       Date:  2015-02       Impact factor: 3.960

2.  TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear.

Authors:  Paola Monti; Paola Ghiorzo; Paola Menichini; Giorgia Foggetti; Paola Queirolo; Alberto Izzotti; Gilberto Fronza
Journal:  Oncol Rep       Date:  2017-08-14       Impact factor: 3.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.